Biond Biologics Ltd., a private biopharmaceutical company, has entered into a partnership with Merck KGaA, Darmstadt, Germany, to support a Phase 1 clinical trial aimed at treating patients with unresectable or metastatic solid tumors. This clinical trial, designated as BND-35-001 (NCT06274437),
In the fast-evolving field of cellular biology, fluorescence imaging has emerged as a revolutionary tool for tracking cellular processes. With its ability to provide detailed and dynamic views of life on a microscopic scale, it has opened new paths for research and understanding, profoundly
Kivu Biosciences, a San Francisco-based biotechnology startup, has made headlines by raising an impressive $92 million in its Series A funding round. This influx of investment will significantly bolster the company's efforts to advance its groundbreaking antibody-drug conjugates (ADCs), which hold
In a significant leap forward for oncology, the U.S. Food and Drug Administration (FDA) has given the green light to Astellas Pharma Inc.'s VYLOY (zolbetuximab-clzb) for treating adults with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or
Gilead Sciences recently announced its decision to withdraw Trodelvy from the market as a treatment for bladder cancer, following disappointing results from its confirmatory TROPiCS-04 clinical trial. This marks a notable shift for a drug that initially showed promise in shrinking tumors and
In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone
